ALMSALUMIS INC.
Pharmaceutical Preparations
- Revenue
- $24M
- Operating margin
- -1886.9%
- EBITDA
- −$450M
- 51% YoY
- Market cap
- —
- Employees
- —
- Net debt / EBITDA
- —
- AI in 10-K
- —
Red flags 1 of 9
- TSR below peersClear—3+ of last 5 years
- High CEO pay despite TSRClear—Median CEO pay ≥ $15M and TSR flag
- Active 13DClear0 filingsActive-intent 13D in 18 months
- Net insider sellingClear$0 netNet sales over $10M in 12 months
- Earnings not backed by cashClear—Cash flow under 80% of net income
- Dilutive SBCFired181% of revenueOver 10% of revenue
- Payouts exceed cash flowClear-0% of cash flowBuybacks + dividends over cash flow
- Goodwill-heavyClear—Over 40% of assets
- Shareholder dissentClear—Any vote under 80% support
Financials
| Metric | FY2023 | FY2024 | FY2025 | YoY |
|---|---|---|---|---|
| Revenue | — | — | $24M | |
| Operating income | −$158M | −$301M | −$454M | 51% |
| Net income | −$155M | −$294M | −$243M | 17% |
| Operating cash flow | −$130M | −$255M | −$370M | 45% |
| Capex | $4M | $2M | $653K | 62% |
| Stock-based comp | $9M | $19M | $44M | 124% |
| Buybacks | $64K | $6K | $17K | 183% |
Deal filings
None.
13D filers
None on file.
Insider trading
- Open-market buys, 12 mo
- $11M · 4
- Open-market sells, 12 mo
- $1M · 2
- Net
- $10M
Pay vs performance
No pay-versus-performance disclosure yet.